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AbstrAct
Introduction An understanding of real-world predictors of 
abatacept retention is limited. We analysed retention rates 
and predictors of abatacept retention in biologic-naïve and 
biologic-failure patients in a 12-month interim analysis of 
the 2-yearAbataCepTIn rOutiNe clinical practice (ACTION) 
study.
Methods ACTION was an international, observational 
study of patients with moderate-to-severe rheumatoid 
arthritis (RA) who initiated intravenous abatacept. In this 
12-month interim analysis, crude abatacept retention 
rates, predictors of retention and European League Against 
Rheumatism (EULAR) response were evaluated in both 
biologic-naïve and biologic-failure patients. Retention by 
rheumatoid factor (RF) and anti-cyclic citrullinated peptide 
(CCP) status was also assessed, in patients with or without 
baseline radiographic erosions, and by body mass index 
(BMI).
Results Overall, 2350/2364 enrolled patients were 
evaluable (674 biologic naїve; 1676 biologic failure). Baseline 
characteristics were largely similar in biologic-naïve and 
biologic-failure groups. Crude retention rates (95% CI) 
at 12 months were significantly higher in biologic-naїve 
(78.1%(74.7% to 81.2%)) versus biologic-failure patients 
(69.9%(67.6% to 72.1%); P<0.001). RF/anti-CCP double 
positivity predicted higher retention in both patient groups, 
and remained associated with higher retention in patients 
with erosive disease. BMI did not impact abatacept retention 
in either patient group, irrespective of RF/anti-CCP serostatus. 
Good/moderate EULAR response rate at 12 months was 
numerically higher in biologic-naїve (83.8%) versus biologic-
failure (73.3%) patients. There were no new safety signals.
Conclusion High levels of intravenous abatacept retention 
in clinical practice were confirmed, particularly in biologic-
naïve patients, including in those with poor RA prognostic 
factors. Retention was unaffected by BMI, regardless of RF/
anti-CCP serostatus.
Trial registration number NCT02109666; retrospectively 
registered 8 April 2014.
InTRoduCTIon
The treatment of rheumatoid arthritis (RA) 
has undergone significant evolution through 
optimisation of conventional and new 
biologic therapies. However, not all patients 
benefit; some discontinue treatment due to a 
lack of response, a change in initial response 
or intolerance. These challenges highlight 
the need to identify predictors of response 
to optimise treatment choice. The identifica-
tion of real-world predictive factors of treat-
ment retention in patients with RA could 
assist rheumatologists with therapeutic deci-
sion-making in clinical practice and support 
personalised medicine.
ORIGINAL ARTICLE
Real-world predictors of 12–month 
intravenous abatacept retention in 
patients with rheumatoid arthritis in the 
ACTION observational study
Rieke Alten,1 Xavier Mariette,2 Hanns-Martin Lorenz,3 Mauro Galeazzi,4 
Alain Cantagrel,5 Hubert G Nüßlein,6 Melanie Chartier,7 Yedid Elbez,8 
Christiane Rauch,9 Manuela Le Bars7
To cite: Alten R, Mariette X, 
Lorenz H-M, et al. Real-world 
predictors of 12–month 
intravenous abatacept retention 
in patients with rheumatoid 
arthritis in the ACTION 
observational study. RMD Open 
2017;3:e000538. doi:10.1136/
rmdopen-2017-000538
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit the 
journal (http:// dx. doi. org/ 10. 
1136/ rmdopen- 2017- 000538 ) 
Received 12 July 2017
Revised 23 November 2017
Accepted 1 December 2017
For numbered affiliations see 
end of article.
Correspondence to
Prof Dr Rieke Alten, Department 
of Internal Medicine, 
Rheumatology, Clinical 
Immunology, and Osteology 
Schlosspark-Klinik University 
Medicine Berlin Germany ;  
 rieke. alten@ schlosspark- klinik. 
de
Rheumatoid arthritis
Key messages
What is already known about this subject?
 ► Rheumatoid factor (RF)-positive and/or anti-cyclic 
citrullinated peptide (CCP)-positive status are 
associated with greater efficacy of abatacept than 
seronegative status in biologic-naïve patients with 
rheumatoid arthritis (RA).
 ► Positivity for both RF and anti-CCP is associated 
with a greater likelihood of abatacept retention than 
single positivity or double negativity in patients with 
previous exposure to one or more biologic.
What does this study add?
 ► Seropositivity is associated with improved 
abatacept retention in both biologic-naïve and 
biologic-failure patients. There was an association 
between seropositivity and improved abatacept 
retention in those with erosive disease.
 ► Body mass index did not affect abatacept retention 
in either biologic-naïve or biologic-failure patients, 
regardless of RF or anti-CCP serostatus.
How might this impact on clinical practice?
 ► An increased knowledge of the combined effect 
of poor prognostic factors for RA and predictors of 
abatacept retention may support clinical decision-
making and personalised treatment strategies.
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Several potential predictors of abatacept retention have 
been identified in real-world studies and include known 
poor prognostic factors in RA. Abatacept retention rates 
are higher for biologic-naïve patients than for those with 
previous failure of a biologic disease-modifying antirheu-
matic drug (DMARD).1 2 Abatacept retention is signifi-
cantly associated with both the presence of anti-cyclic 
citrullinated peptide (CCP) and rheumatoid factor (RF), 
and seems to be unaffected by weight/body mass index 
(BMI).3–7 However, available real-world data on predic-
tors of abatacept retention are derived from analyses 
of mostly biologic-failure patients, and data for biolog-
ic-naïve patients are limited to short-term analyses.4 7 This 
analysis was designed to compare 1-year retention rates 
for abatacept in both biologic-naïve and biologic-failure 
patients.
The international AbataCepT In rOutiNe clinical prac-
tice (ACTION) study aims to provide prospective, real-
world data on abatacept retention in patients with RA 
and to identify predictors of abatacept retention. Three 
successive patient cohorts were recruited: biologic-naïve 
or biologic-failure patients (cohort A), biologic-naïve 
patients only (cohort B) and biologic-failure patients 
only (cohort C). Previous analyses of biologic-failure 
patients enrolled in ACTION found that predictors 
of higher abatacept retention included anti-CCP posi-
tivity, RF and anti-CCP double positivity, prior exposure 
to <2 anti-tumour necrosis factor (TNF) agents, cardio-
vascular comorbidity and residence in Greece or Italy 
versus Germany.5 8 In the current interim analysis of both 
biologic-naïve and biologic-failure patients enrolled in 
ACTION, we assessed the predictors of abatacept reten-
tion at 12 months in both patient groups, with particular 
focus on patients with poor prognostic factors of disease 
progression at baseline.
MeTHods
study design and analysis population
Study design and ethics approvals for the ACTION study 
have been reported previously.9 Briefly, ACTION was a 
2-year, international, multicentre, observational cohort 
study of patients who initiated intravenous abatacept in 
routine clinical practice across Europe (Austria, Belgium, 
Czech Republic, Denmark, France, Germany, Greece, 
Italy, Netherlands, Spain and Switzerland) and Canada 
(see online supplementary figure S1).9 Participating 
countries were required to have marketing authorisation 
for abatacept and a reimbursement policy. No product 
was provided to physicians or patients by the study 
sponsor.
Enrolled patients provided informed consent (written 
or not, according to the local laws), were aged ≥18 years, 
and had moderate-to-severe RA as defined by the Amer-
ican College of Rheumatology 1987 revised criteria10 
and consistent with the abatacept label in Europe and 
Canada.11 12 Any patients already enrolled in a randomised 
clinical trial were excluded. Patients were enrolled over 
three periods (cohorts A, B and C), either prospectively 
at initiation of intravenous abatacept or retrospectively 
within 3 months of initiation of intravenous abatacept 
(see online supplementary figure S2). In Europe, intra-
venous abatacept plus methotrexate (MTX) was initially 
approved for the treatment of moderate-to-severe RA 
in patients with insufficient response or intolerance 
to anti-TNF therapy (21 May 2007 to 30 June 2010). 
Approval was later extended to patients with inadequate 
response to MTX and/or anti-TNF agents (1 July 2010 
onwards). In Canada, abatacept is approved as mono-
therapy or in combination with a DMARD in patients with 
an inadequate response to DMARDs and/or anti-TNF 
agents (29 June 2006 onwards).11 12 Cohort A included 
patients enrolled between May 2008 and December 2010 
who were biologic naïve or had failed ≥1 prior biologic 
agent (see online supplementary figure S1,S2). Cohort 
B included patients enrolled between September 2010 
and December 2013 who were biologic naïve (see online 
supplementary figure S1,S2). Cohort C included patients 
enrolled between October 2011 and December 2013 who 
had failed ≥1 prior biologic agent, and was included to 
investigate whether the change in abatacept approval led 
to its use in earlier lines of therapy (see online supple-
mentary figure S1,S2).
Patients were followed for up to 2 years or, if the patient 
discontinued abatacept before the 2-year time point, up 
to 6 months after abatacept discontinuation. Follow-up 
visits were approximately every 3 months (according to 
clinical practice). The data cut-off date for this analysis 
was May 2015.
Abatacept retention
Abatacept retention over 12 months was evaluated 
in biologic-naïve patients (cohorts A and B), and in 
biologic-failure patients (cohorts A and C), including 
by number of previously failed biologics. Retention 
was defined as consecutive time on treatment. Biolog-
ic-failure patients were those in whom a previous biologic 
either was ineffective or had caused safety or tolerability 
concerns, patients in clinical remission or in whom 
there was a major improvement of symptoms following 
a previous biologic, or patients who had discontinued a 
previous biologic for any reason. The treating physician 
documented discontinuation from abatacept treatment 
at any follow-up visit. If patients discontinued abatacept, 
exposure to abatacept was defined as the time between 
the date of the first and the last infusion plus 30 days.
Clinical efficacy of abatacept
Clinical response to abatacept at 12 months, by treat-
ment line, was assessed using the European League 
Against Rheumatism (EULAR) response criteria based 
on 28-joint Disease Activity Score (DAS28) (erythrocyte 
sedimentation rate (ESR) or C reactive protein (CRP), 
derived based on core components), and classified as 
good, moderate or no response.13 Remission was defined 
based on DAS28 (ESR or CRP derived based on core 
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components) (<2.6), Clinical Disease Activity Index 
(CDAI) (≤2.8), Simplified Disease Activity Index (SDAI) 
(≤3.3) and Boolean criteria.14
Predictors of abatacept retention
Potential predictors of abatacept retention were assessed 
for both biologic-naïve and biologic-failure patients and 
included baseline demographic data (RF, anti-CCP and 
BMI), disease characteristics (including Patient Global 
Assessment (PtGA) of pain), comorbidities (including 
diabetes mellitus, chronic obstructive pulmonary disease 
(COPD), cardiac disorders, neoplasms (benign, malig-
nant and unspecified) and psychiatric disorders), and 
previous and current treatments. To allow between-
country effects to be explored appropriately, only patients 
from countries that recruited ≥10 patients were included 
in the analyses; Germany was the reference country as it 
was where the highest number of study participants was 
enrolled.
The impact of RF/anti-CCP on abatacept retention 
was assessed in patients with and without erosions. Simi-
larly, BMI impact was assessed in patients who were RF/
anti-CCP double positive or double negative (BMI: under-
weight/normal: <25 kg/m2, overweight: 25–<30 kg/m2 
and obese: ≥30 kg/m2).
safety
Safety was assessed in accordance with local regulations, 
and registered with the drug manufacturer’s global phar-
macovigilance department. The relationship between 
the study drug and any serious adverse event (SAE) was 
evaluated by the treating physician. An SAE was defined 
as an AE that was fatal or life threatening, required or 
extended hospitalisation (except pregnancy), resulted in 
persistent or significant disability or incapacity, induced 
a congenital anomaly or birth defect, or was considered 
an important medical event. All deaths were documented 
whether or not they were treatment related. Safety data 
are presented for the full study population, regardless of 
prior biologic treatment.
statistical analyses
Baseline characteristics and demographic data were 
reported using descriptive statistics including sample 
size, proportions or mean and SD. For each treatment 
line, crude abatacept retention rates over 12 months 
with corresponding 95% CIs were estimated by Kaplan-
Meier analysis and compared using log-rank tests. Right 
censoring at the time of last information available was 
used for patients lost to follow-up without documented 
abatacept discontinuation and with follow-up <12 
months.
To identify significant predictors of abatacept reten-
tion, clinically relevant variables, known risk factors and 
potential predictive factors for discontinuation with 
significance in univariable models (P≤0.20) and no collin-
earity were entered into multivariable Cox proportional 
hazards regression models. Factors with P≤0.10 after 
backward selection were retained in the models. Analyses 
were performed separately on biologic-naïve and biolog-
ic-failure patients, and additional subgroup analyses were 
also performed. The impact of RF/anti-CCP double-pos-
itive versus double-negative status was tested separately 
in patient subgroups with and without joint erosions at 
baseline. In addition, the impact of BMI (forced into the 
multivariable model) was tested after stratification by 
RF/anti-CCP status. Results are presented as HRs with 
corresponding 95% CIs and P values. The HRs were 
statistically significant when the 95% CIs did not cross 1.
ResulTs
Patients
In total, 2364 patients were enrolled, of whom 2350 were 
evaluable (online supplementary figure S1,S3). Between 
May 2008 and December 2010 (cohort A, biologic naїve/
biologic failure), 1137 patients were enrolled from nine 
countries, and 1131 of whom were evaluable (see online 
supplementary figure S1). Between September 2010 and 
December 2013 (cohort B, biologic naïve only), 555 
patients were enrolled from eight countries, and 552 of 
whom were evaluable (see online supplementary figure 
S1A). Between October 2011 and December 2013 (cohort 
C, biologic failure only), 672 patients were enrolled from 
eight countries, and 667 of whom were evaluable (see 
online supplementary figure S1B).
Biologic-naïve patients from cohorts A and B were 
pooled, as were biologic-failure patients from cohorts A 
and C. Among all evaluable patients, 674 (28.7%) were 
biologic naїve and 1676 (71.3%) had failed ≥1 prior 
biologic: 728 (43.4%) had failed 1 biologic agent and 948 
(56.6%) had failed ≥2 biologic agents; 1605 (95.8%) had 
failed an anti-TNF agent (online supplementary figure 
S3).
Overall, the biologic-naïve and biologic-failure groups 
represented a typical population of patients with RA 
who have long-standing, erosive and moderate-to-severe 
disease. The two patient groups had similar baseline 
demographic data and clinical characteristics; however, 
biologic-naïve patients had shorter disease duration, a 
lower proportion of women, fewer patients with joint 
erosions overall and in combination with RF/anti-CCP 
positivity, fewer patients who received previous RA treat-
ments (other than MTX) and a higher proportion of 
patients with certain comorbidities (cardiac disorders, 
COPD and neoplasms; table 1).
Abatacept retention
Over the 12-month follow-up, 139/674 (20.6%) biolog-
ic-naïve and 478/1676 (28.5%) biologic-failure patients 
discontinued therapy. The main reasons for discontinu-
ation over 12 months were similar in biologic-naïve and 
biologic-failure patients, with 69.2% of discontinuations 
due to lack of efficacy in both groups, and 24.8% and 
23.1% due to intolerance, respectively (online supple-
mentary table S1). Crude retention rates (95% CIs) 
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Table 1 Baseline characteristics
Biologic naïve (n=674) Biologic failure (n=1676)
Age, years 59.9 (12.7) 57.0 (12.5); n=1675
Female, n (%) 496 (73.6) 1379 (82.3)
BMI, kg/m2 27 (5.4); n=645 27.1 (5.6); n=1595
BMI, n (%)
  <25 kg/m² 266 (41.2) 648 (40.6)
  25–<30 kg/m² 224 (34.7) 542 (34.0)
  ≥30–<35 kg/m² 104 (16.1) 266 (16.7)
  ≥35 kg/m² 51 (7.9) 139 (8.7)
RA duration, years 7.2 (8.2); n=669 12.1 (9.2); n=1669
Number of previous biologics, n (%)
  1 NA 728 (43.4) 
  2 589 (35.1) 
  >2 359 (21.5) 
Previous csDMARDs, n (%)
  MTX 621 (92.1) 1550 (92.5)
  Leflunomide 279 (41.4) 951 (56.7) 
  Hydroxychloroquine/chloroquine 229 (34.0) 680 (40.6) 
  Sulfasalazine 148 (22.0) 577 (34.4) 
TJC28 9.0 (6.5); n=634 10.4 (7.2); n=1598
SJC28 6.6 (5.0); n=642 7.0 (5.6); n=1606
DAS28 (ESR)* 5.3 (1.2); n=582 5.5 (1.3); n=1422
DAS28 (CRP)* 4.8 (1.1); n=568 5.0 (1.1); n=1412
CDAI* 27.5 (11.5); n=565 30.0 (12.9); n=1388
SDAI* 29.1 (12.0); n=526 31.8 (13.6); n=1280
PtGA (100 mm VAS) 61.9 (20.3); n=621 65.4 (19.9); n=1538
RF and anti-CCP antibody status, n/N (%)
  Double negativity 127/514 (24.7) 267/1166 (22.9) 
  Single positivity 77/514 (15.0) 183/1166 (15.7) 
  Double positivity 310/514 (60.3) 716/1166 (61.4) 
Radiographic erosion, n/N (%) 353/608 (58.1) 1034/1445 (71.6)
Radiographic erosion plus RF and anti-CCP double positivity, 
n/N (%)
184/490 (37.6) 512/1085 (47.2)
≥1 comorbidity, n (%) 517 (76.7) 1224 (73.0)
  Diabetes mellitus 85 (12.6) 207 (12.4)
  COPD 70 (10.4) 129 (7.7)
  Cardiac disorders 61 (9.1) 125 (7.5)
  Neoplasms 33 (4.9) 41 (2.4)
   Benign 5 (0.7) 10 (0.6) 
   Malignant 17 (2.5) 20 (1.0) 
   Unspecified † 11 (1.6) 13 (0.8) 
  Psychiatric disorders 18 (2.7) 41 (2.4)
   Depressive disorders 13 (1.9) 37 (2.2) 
Data are mean (SD) unless indicated otherwise.
*Calculated.
†Neoplasms not classified as either benign or malignant. Information on malignancies at baseline was not routinely collected.
BMI, body mass index; CCP, cyclic citrullinated peptide; CDAI, Clinical Disease Activity Index; COPD, chronic obstructive pulmonary disease; 
CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28, 28-joint Disease Activity Score; 
ESR, erythrocyte sedimentation rate; MTX, methotrexate; PtGA, Patient Global Assessment of disease activity; RA, rheumatoid arthritis; RF, 
rheumatoid factor; SDAI, Simplified Disease Activity Index; SJC, swollen joint count; TJC, tender joint count; VAS, Visual Analogue Scale.
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Figure 1 (A) Crude retention rate over 12 months of abatacept treatment and (B) crude retention rate over 12 months of 
abatacept treatment by line of treatment. TNF, tumour necrosis factor.
over 12 months were significantly higher in biolog-
ic-naïve versus biologic-failure patients (78.1% (74.7% to 
81.2%) vs 69.9% (67.6% to 72.1%), respectively; P<0.001; 
figure 1A). In most cases, the biologic that failed was an 
anti-TNF agent. Crude retention rates over 12 months 
were higher in biologic-naïve patients versus patients who 
had failed 1 and ≥2 previous anti-TNF(s) (figure 1B).
Predictors of retention
Overall, 2201/2350 (93.7%) evaluable patients were 
considered for the multivariable analysis. In total, 18 clin-
ically relevant variables, known risk factors and potential 
predictive factors for discontinuation in biologic-naïve 
patients, and 31 in biologic-failure patients, were iden-
tified from the univariable analysis and entered into the 
multivariable models.
For biologic-naïve patients, predictors of higher 
abatacept retention were RF and anti-CCP double posi-
tivity versus double negativity, and residence in Canada, 
Greece or Italy versus Germany as reference (figure 2). 
Neoplasms (mainly endocrine and breast) and psychi-
atric disorders (mainly depression) were associated with 
lower retention (figure 2).
In an exploratory analysis, the known poor disease prog-
nostic factors of seropositivity and joint erosions were also 
investigated. After stratification of biologic-naïve patients 
by baseline erosion status, RF and anti-CCP double posi-
tivity versus double negativity remained associated with 
higher retention only in patients with erosive disease at 
baseline (single positivity: HR (95% CI) 0.90 (0.45 to 1.81); 
double positivity: 0.55 (0.32 to 0.94); P=0.05; figure 3). 
When forced into the multivariable model, BMI did not 
significantly impact abatacept retention in the subgroups 
of biologic-naïve patients who were RF/anti-CCP double 
positive (BMI 25–<30 kg/m2: HR (95% CI) 0.49 (0.24 to 
2.03); BMI≥30 kg/m2: 0.62 (0.28 to 1.38); P=0.142) or 
double negative (BMI 25–<30 kg/m2: 1.55 (0.45 to 3.00); 
BMI≥30 kg/m2: 0.64 (0.23 to 1.75); P=0.518) at baseline 
(online supplementary figure S4).
In biologic-failure patients, predictors of higher abata-
cept retention were RF and anti-CCP single and double 
positivity versus double negativity (P<0.001), country 
of residence (P<0.001), with residence in Greece (HR 
(95% CI) 0.38 (0.22 to 0.66)) or Italy (0.63 (0.44 to 
0.91)) predicting higher retention versus Germany as 
a reference, MTX combination therapy with or without 
other conventional synthetic DMARDs versus abata-
cept monotherapy (0.69 (0.56 to 0.86); P=0.002) and 
cardiac disorders (0.66 (0.43 to 1.00); P=0.049; figure 4). 
Lower retention was associated with exposure to ≥2 prior 
biologics (HR 1.23; 95% CI 1.02 to 1.48; P=0.034), higher 
PtGA of pain score (≥70 mm on a Visual Analogue Scale; 
HR 1.27 (95% CI 1.04 to 1.54); P=0.520) and residence 
in Switzerland (HR 1.81; 95% CI 1.12 to 2.93) (figure 4). 
After stratification of biologic-failure patients by baseline 
erosion status, RF and anti-CCP double positivity versus 
double negativity remained associated with higher reten-
tion only in patients with erosive disease at baseline (single 
positivity: HR (95% CI) 0.55 (0.40 to 0.76); double posi-
tivity: 0.54 (0.40 to 0.73); P<0.001; online supplementary 
table S2). In the exploratory analysis, testing the impact 
of BMI on abatacept retention by RF/anti-CCP serostatus 
in biologic-failure patients generated similar results to 
those observed for biologic-naïve patients: no significant 
impact of BMI on abatacept retention was observed (data 
not shown).
Clinical efficacy of abatacept
At 12 months, a significantly greater proportion of 
biologic-naïve versus biologic-failure patients achieved 
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Figure 2 Multivariable model of abatacept retention in biologic-naïve patients. P values are pooled across each category. 
HRs are significant when the 95% CIs do not overlap 1. *Neoplasms were mainly endocrine and breast cancer. †Psychiatric 
disorders were mainly depression. CCP, cyclic citrullinated peptide; RF, rheumatoid factor.
a good or moderate EULAR response (83.8% vs 73.3%, 
P<0.001; figure 5). Remission, as defined by DAS28 (ESR 
or CRP)<2.6, CDAI, SDAI and Boolean criteria, was also 
achieved in a greater proportion of biologic-naïve versus 
biologic-failure patients (30.8% vs 21.9%, P=0.003; 44.5% 
vs 35.0%, P=0.004; 18.9% vs 12.6%, P=0.006; 18.4% vs 
12.2%, P=0.01; and 15.0% vs 9.4%, P=0.01, respectively).
safety
At the time of this 1-year interim analysis of ACTION, 
a total of 376 SAEs had been reported in 198 of 2364 
patients evaluated (8.4%), leading to the discontinu-
ation of abatacept in 95 (4.0%) patients. Overall, 26 
deaths were reported during the treatment period 
(online supplementary table S3). Two deaths were due 
to an opportunistic infection (Pneumocystis jirovecii and 
Candida). Serious infections were reported in 76 patients 
(3.2%); there was one case of latent tuberculosis and 
four cases of opportunistic infections (two Pneumocystis 
jirovecii, one Cytomegalovirus, one Candida). The majority 
of serious infections were of the upper respiratory tract. 
A total of 24 neoplasms (benign, malignant and unspec-
ified) were reported, two of which were pre-existing 
malignancies at baseline (brain malignancy and Bowen’s 
disease). Serious immune system disorders were reported 
in 20 patients, serious cardiac disorders in 17 patients 
and serious vascular disorders in 16 patients.
dIsCussIon
As the number of available RA treatment regimens with 
unique mechanisms of action increases, a shift towards 
personalised medicine is necessary to ensure that patients 
receive the most appropriate treatment early in the course 
of disease to arrest or slow disease progression, and to 
prevent the accumulation of irreversible disability. Real-
world, long-term treatment retention data in RA could 
serve as a surrogate measure of the benefit-to-risk ratio, 
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Figure 3 Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without 
radiographic erosion at baseline. P values are pooled across each category. HRs are significant when the 95% CIs do not 
overlap 1. CCP, cyclic citrullinated peptide; RF, rheumatoid factor.
complementing the data from the defined patient popu-
lations of randomised controlled trials with those from 
more diverse patient populations. In addition, the heter-
ogeneous nature of both RA itself and the response to RA 
treatment highlights the value of predictors of treatment 
response in informed clinical decision-making.
This is the first analysis of ACTION to include a 
cohort of biologic-naïve patients for whom predictors 
of abatacept retention were detected using a multivari-
able analysis. In this analysis of a typical RA population 
with long-standing, erosive and moderate-to-severe 
disease, 12-month abatacept retention rates were higher 
in biologic-naïve versus biologic-failure patients (78% vs 
70%, respectively), consistent with previous analyses of 
ACTION,5 and with independent registry data for abata-
cept.1 15 Higher retention rates in biologic-naïve versus 
biologic-failure patients with RA have similarly been 
reported for other biologics (76% vs 65% (infliximab), 
72% vs 60% (etanercept), 68% vs 57% (adalimumab) 
and 81% vs 54%–66% (tocilizumab), respectively).16 17
Our analysis identified several predictors associated with 
higher rates of abatacept retention following 12 months 
of treatment in both biologic-naïve and biologic-failure 
patients, and included the poor prognostic factor of RF/
anti-CCP double positivity.18 The predictors of abata-
cept retention identified in this analysis were similar to 
those identified in previous 12-month and 24-month 
interim analyses of biologic-failure patients enrolled in 
ACTION,5 8 and in other registry studies.3 6Patients who 
are anti-CCP positive tend to develop more severe, erosive 
disease.19 Interestingly, further investigation of the 
biologic-naïve and biologic-failure groups in this analysis 
revealed that RF/anti-CCP double positivity remained 
predictive of abatacept retention in patients with erosive 
disease at baseline, that is,  in those with more than one 
poor prognostic factor and for whom a more aggressive 
approach to treatment is recommended.18
Anti-CCP and RF positivity have also been shown to 
be associated with a better clinical response to abata-
cept in both randomised clinical trials and real-world 
settings.7 20–25 In contrast, evidence for the effect of 
serostatus on retention or efficacy of anti-TNF agents and 
other biologics is conflicting.26–32
The association between response to abatacept and 
anti-CCP positivity is most intriguing. It could reflect 
the upstream mechanism of abatacept, whereby costim-
ulation blockade inhibits T-helper cell activation with a 
subsequent impact on B cells and autoantibody produc-
tion.33 34 Furthermore, seropositive and seronegative 
patients may differ in terms of disease heterogeneity. 
Compared with patients who are seronegative, seroposi-
tive patients may represent a more homogeneous popula-
tion who are likely to respond to a treatment that targets 
underlying RA pathophysiology, such as abatacept.
Several studies have shown that obesity can negatively 
affect clinical response to anti-TNF agents and some other 
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Figure 4 Multivariable model of abatacept retention in biologic-failure patients. P values are pooled across each category. 
HRs are significant when the 95% CIs do not overlap 1. CCP, cyclic citrullinated peptide; DMARD, disease-modifying 
antirheumatic drug; MTX, methotrexate; RF, rheumatoid factor; VAS, Visual Analogue Scale.
biologics in RA35–37; the effect of weight/BMI on tocili-
zumab efficacy is unclear.38 39 In contrast, in this analysis, 
BMI did not impact abatacept retention at 12 months in 
either biologic-naïve or biologic-failure patients, consis-
tent with previous analyses of abatacept real-world data.3–5 
Furthermore, BMI did not impact abatacept retention 
in either biologic-naïve or biologic-failure patients who 
were also seropositive for both RF and anti-CCP.
Among patients with RA, there is a high preva-
lence of comorbidities such as atherosclerosis-related 
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Figure 5 Percentage of patients achieving EULAR response* at 12 months by treatment line. n represents the number of 
patients with available data. *EULAR response was based on 28-joint Disease Activity Score, erythrocyte sedimentation rate 
or C reactive protein (collected). †Biologic-naïve versus biologic-failure patients who achieved a good or moderate EULAR 
response (83.8% vs 73.3%, P<0.001). EULAR, European League Against Rheumatism.
cardiovascular diseases, some cancers and infections.40 
Although the overall risk of malignancy is higher in 
patients with RA compared with the general popula-
tion, this risk appears to be unaffected by treatment with 
abatacept or other biologics.41–44 In the current study, 
neoplasms (mainly endocrine and breast) and psychiatric 
disorders (mainly depression) were associated with lower 
retention in biologic-naïve patients, whereas cardiovas-
cular disease was not associated with a higher risk of abata-
cept discontinuation, consistent with previous findings in 
biologic-failure patients.5 45 Any interpretation of these 
findings would be highly speculative; however, abatacept 
could be regarded as suitable for the treatment of RA in 
patients with cardiovascular disease. The long-term safety 
of intravenous abatacept is well established, and obser-
vational data suggest that the risk of acute myocardial 
infarction is lower in patients with RA initiating abatacept 
than in those initiating some anti-TNF agents.46 47 The 
question of the impact of comorbidities on drug reten-
tion does deserve further investigation.
Differences in abatacept retention by participating 
country were observed in this patient population, consis-
tent with findings from a pooled analysis of data from Euro-
pean registries.1 In the absence of local reimbursement 
restrictions, these differences may be indicative of national 
variance in prescribing guidelines and clinical practice, 
access to biologics, cultural differences or in the regulatory 
approval of abatacept and other RA agents.1 48 49
Limitations of this analysis are inherent in observational 
real-world studies, including the absence of an active 
comparator and loss of patients to follow-up, which can 
result in a substantial number of missing clinical measure-
ments. In addition, physicians may have waited longer 
before deciding that abatacept treatment was ineffective 
in patients who had an inadequate response to multiple 
biologic agents prior to initiating abatacept, potentially 
affecting the observed abatacept retention rate.
Conclusions
Higher abatacept retention and better clinical outcomes 
were seen in patients who received abatacept as the 
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first-line biologic versus later treatment. RF/anti-CCP 
positivity was identified as a predictor for better retention 
in both biologic-naïve and biologic-failure patients, and 
RF/anti-CCP double positivity remained associated with 
higher retention in patients with erosive disease. BMI 
had no impact on abatacept retention in RF/anti-CCP 
double-positive biologic-naïve or biologic-failure patients. 
An increased awareness of the combined effect of predic-
tive factors of treatment retention may support person-
alised, clinical decision-making in patients with moder-
ate-to-severe RA in the real-world setting.
Consent to participate
The ACTION study was conducted in accordance with 
the Declaration of Helsinki and was consistent with the 
International Conference on Harmonisation Good 
Clinical Practice Guidelines50 and Good Epidemiolog-
ical Practice Guidelines.51 Enrolled patients provided 
informed consent (written or not, according to the local 
laws), were aged over 18 years, of either sex, with an estab-
lished diagnosis of moderate-to-severe RA as defined by 
the American College of Rheumatology 1987 revised 
criteria.10 Any patients already enrolled in an interven-
tional RA clinical trial were excluded.
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